120 related articles for article (PubMed ID: 7528534)
1. Interferon alfa-2a modifies the course of subfoveal and juxtafoveal choroidal neovascularisation.
Engler C; Sander B; Villumsen J; Lund-Andersen H
Br J Ophthalmol; 1994 Oct; 78(10):749-53. PubMed ID: 7528534
[TBL] [Abstract][Full Text] [Related]
2. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Pharmacological Therapy for Macular Degeneration Study Group.
Arch Ophthalmol; 1997 Jul; 115(7):865-72. PubMed ID: 9230826
[TBL] [Abstract][Full Text] [Related]
3. Interferon alfa-2a in the treatment of subfoveal choroidal neovascularization.
Thomas MA; Ibanez HE
Am J Ophthalmol; 1993 May; 115(5):563-8. PubMed ID: 7683842
[TBL] [Abstract][Full Text] [Related]
4. Treatment of choroidal neovascularisation in age-related macular degeneration with interferon alfa-2a and alfa-2b.
Gillies MC; Sarks JP; Beaumont PE; Hunyor AB; McKay D; Kearns M; McClusky PJ; Sarks SH
Br J Ophthalmol; 1993 Dec; 77(12):759-65. PubMed ID: 7509184
[TBL] [Abstract][Full Text] [Related]
5. Treatment of choroidal neovascularization in age-related macular degeneration with interferon alpha-2a: a short term, nonrandomized pilot study.
Thoelen A; Menozzi M; Huber C; Messmer E
Ger J Ophthalmol; 1995 May; 4(3):137-43. PubMed ID: 7545047
[TBL] [Abstract][Full Text] [Related]
6. Interferon alpha-2a treatment of patients with subfoveal neovascular macular degeneration. A pilot investigation.
Engler CB; Sander B; Koefoed P; Larsen M; Vinding T; Lund-Andersen H
Acta Ophthalmol (Copenh); 1993 Feb; 71(1):27-31. PubMed ID: 7682747
[TBL] [Abstract][Full Text] [Related]
7. Interferon alpha-2a in the treatment of exudative senile macular degeneration.
Jaakkola A; Anttila PM; Immonen I
Acta Ophthalmol (Copenh); 1994 Oct; 72(5):545-9. PubMed ID: 7534027
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with interferon alfa-2a for exudative age-related macular degeneration.
Kirkpatrick JN; Dick AD; Forrester JV
Br J Ophthalmol; 1993 Dec; 77(12):766-70. PubMed ID: 7509185
[TBL] [Abstract][Full Text] [Related]
9. The treatment of choroidal neovascular membranes by alpha interferon. An efficacy and toxicity study.
Chan CK; Kempin SJ; Noble SK; Palmer GA
Ophthalmology; 1994 Feb; 101(2):289-300. PubMed ID: 7509472
[TBL] [Abstract][Full Text] [Related]
10. Interferon for subfoveal choroidal neovascularisation.
Groeneveld E; Eliadis P
Aust N Z J Ophthalmol; 1993 May; 21(2):133-4. PubMed ID: 7687445
[No Abstract] [Full Text] [Related]
11. Treatment of subfoveal choroidal neovascular membranes with systemic interferon-alpha 2a.
Loughnan MS; Heriot WJ; O'Day J
Aust N Z J Ophthalmol; 1992 Aug; 20(3):173-5. PubMed ID: 1280447
[TBL] [Abstract][Full Text] [Related]
12. Interferon alpha-2a for subfoveal neovascularization in age-related macular degeneration.
Poliner LS; Tornambe PE; Michelson PE; Heitzmann JG
Ophthalmology; 1993 Sep; 100(9):1417-24. PubMed ID: 8371932
[TBL] [Abstract][Full Text] [Related]
13. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study.
Alpsoy E; Durusoy C; Yilmaz E; Ozgurel Y; Ermis O; Yazar S; Basaran E
Arch Dermatol; 2002 Apr; 138(4):467-71. PubMed ID: 11939808
[TBL] [Abstract][Full Text] [Related]
14. Interferon alfa-2a in the treatment of exudative age-related macular degeneration.
Lewis ML; Davis J; Chuang E
Graefes Arch Clin Exp Ophthalmol; 1993 Nov; 231(11):615-8. PubMed ID: 8258394
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal interferon alpha-2b for the treatment of neovascular age-related macular degeneration: a pilot study.
Kertes PJ; Britton WA; Leonard BC
Can J Ophthalmol; 1997 Apr; 32(3):185-8. PubMed ID: 9131284
[No Abstract] [Full Text] [Related]
16. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis.
Onal S; Kazokoglu H; Koc A; Akman M; Bavbek T; Direskeneli H; Yavuz S
Arch Ophthalmol; 2011 Mar; 129(3):288-94. PubMed ID: 21402983
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of age-associated macular degeneration with interferon-alfa-2a].
Thölen A; Kain H; Messmer E
Ophthalmologe; 1993 Jun; 90(3):279-82. PubMed ID: 8334332
[TBL] [Abstract][Full Text] [Related]
18. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
19. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
